Fremont, California
Boehringer Ingelheim’s Fremont, California facility in the San Francisco Bay Area is the company’s only US biopharmaceutical manufacturing site. Established in 2011 and expanded in 2018, the facility is dedicated to the manufacture of monoclonal antibody medicines and other proteins from mammalian cell culture technology.
The 300,000 square-foot facility provides fully integrated biologics development and manufacturing capabilities spanning the complete value chain, from process & analytical development, to clinical and commercial scale drug substance manufacturing, all the way through aseptic fill & finish.